Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580

被引:22
|
作者
Sumida, T [1 ]
Otani, H [1 ]
Kyoi, S [1 ]
Okada, T [1 ]
Fujiwara, H [1 ]
Nakao, Y [1 ]
Kido, M [1 ]
Imamura, H [1 ]
机构
[1] Kansai Med Univ, Dept Thorac & Cardiovasc Surg, Cardiovasc Res Ctr, Moriguchi, Osaka 5708507, Japan
关键词
necrosis; contractility;
D O I
10.1152/ajpheart.01183.2004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
p38 MAP kinase activation is known to be deleterious not only to mitochondria but also to contractile function. Therefore, p38 MAP kinase inhibition therapy represents a promising approach in preventing reperfusion injury in the heart. However, reversal of p38 MAP kinase-mediated contractile dysfunction may disrupt the fragile sarcolemma of ischemic-reperfused myocytes. We, therefore, hypothesized that the beneficial effect of p38 MAP kinase inhibition during reperfusion can be enhanced when contractility is simultaneously blocked. Isolated and perfused rat hearts were paced at 330 rpm and subjected to 20 min of ischemia followed by reperfusion. p38 MAP kinase was activated after ischemia and early during reperfusion (<30 min). Treatment with the p38 MAP kinase inhibitor SB-203580 (10 mu M) for 30 min during reperfusion, but not the c-Jun NH2-terminal kinase inhibitor SP-600125 (10 mu M), improved contractility but increased creatine kinase release and infarct size. Cotreatment with SB-203580 and the contractile blocker 2,3-butanedione monoxime (BDM, 20 mM) or the ultra-short-acting beta-blocker esmorol (0.15 mM) for the first 30 min during reperfusion significantly reduced creatine kinase release and infarct size. In vitro mitochondrial ATP generation and myocardial ATP content were significantly increased in the heart cotreated with SB-203580 and BDM during reperfusion. Dystrophin was translocated from the sarcolemma during ischemia and reperfusion. SB-203580 increased accumulation of Evans blue dye in myocytes depleted of sarcolemmal dystrophin during reperfusion, whereas cotreatment with BDM facilitated restoration of sarcolemmal dystrophin and mitigated sarcolemmal damage after withdrawal of BDM. These results suggest that treatment with SB-203580 during reperfusion aggravates myocyte necrosis but concomitant blockade of contractile force unmasks cardioprotective effects of SB-203580.
引用
收藏
页码:H2726 / H2734
页数:9
相关论文
共 50 条
  • [21] Interactions between SB202190 and SB203580 with the CCK1 receptor and CCK analogues with P38 MAP kinase
    Morel, C
    Ibarz, G
    Oiry, C
    Gagne, D
    Galleyrand, JC
    Martinez, J
    REGULATORY PEPTIDES, 2004, 122 (01) : 32 - 32
  • [22] The effect of a second generation inhibitor of p38 MAP kinase on platelet function
    Covic, L
    Mohanlal, R
    Kuliopulos, A
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) : E68 - E68
  • [23] The p38 MAPK inhibitor, SB203580, inhibits cell invasion by Neospora caninum
    Xiaoxia Jin
    Pengtao Gong
    Guojiang Li
    Xichen Zhang
    Jianhua Li
    Parasitology Research, 2017, 116 : 813 - 819
  • [24] The p38 MAPK inhibitor, SB203580, inhibits cell invasion by Neospora caninum
    Jin, Xiaoxia
    Gong, Pengtao
    Li, Guojiang
    Zhang, Xichen
    Li, Jianhua
    PARASITOLOGY RESEARCH, 2017, 116 (02) : 813 - 819
  • [25] Discovery of a clinical prodrug of a p38α MAP kinase inhibitor
    Liu, Chunjian
    Lin, James
    Hynes, John, Jr.
    Wu, Hong
    Wrobleski, Stephen
    Lin, Shuqun
    Dhar, Murali
    Vrudhula, Vivekananda M.
    Sun, Hung-Hui
    Chao, Sam
    Zhao, Rulin
    Wang, Bei
    Chen, Bang-Chi
    Everlof, Gerry
    Gesenberg, Christoph
    Zhang, Hongjian
    Marathe, Punit H.
    McIntyre, Kim
    Gillooly, Kathleen
    Shuster, David
    Mckinnon, Murray
    Dodd, John H.
    Barrish, Joel C.
    Schieven, Gary L.
    Leftheris, Katerina
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [26] Immunotoxicological assessment of a p38 MAP kinase inhibitor.
    Furst, SM
    Komocsar, WJ
    Burleson, FC
    Peachee, V
    TOXICOLOGICAL SCIENCES, 2003, 72 : 375 - 375
  • [27] Development of a Practical Synthesis of a p38 MAP Kinase Inhibitor
    Thiel, Oliver R.
    Aclirnatowicz, Michal
    Bemard, Charles
    Wheeler, Philip
    Savarin, Cecile
    Correll, Tiffany L.
    Kasparian, Annie
    Allgeier, Alan
    Bartberger, Michael D.
    Tan, Helming
    Larsen, Robert D.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2009, 13 (02) : 230 - 241
  • [28] The Utility of the Minipig in P38 Map Kinase Inhibitor Testing
    Schutzsack, J.
    Gibbs, A.
    Parish, J.
    Gill, K.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2010, 29 (01) : 94 - 94
  • [29] The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway
    Birkenkamp, KU
    Tuyt, LML
    Lummen, C
    Wierenga, LTJ
    Kruijer, W
    Vellenga, E
    BRITISH JOURNAL OF PHARMACOLOGY, 2000, 131 (01) : 99 - 107
  • [30] Blockade of p38 MAP kinase abolishes ischemic preconditioning in pigs
    Belosjorow, S
    Schulz, M
    Gres, P
    Jansen, J
    Michel, M
    Heusch, G
    CIRCULATION, 2001, 104 (17) : 100 - 100